Incyte Corporation (INCY)Healthcare | Biotechnology | Wilmington, United States | NasdaqGS
113.07 USD
-0.20
(-0.177%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 112.30 -0.77 (-0.770%) ⇩ (Oct. 16, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 9:43 a.m. EDT
The long-term outlook remains robust despite a recent price correction. Fundamentals are exceptional, with revenue and earnings growth accelerating to 37.7% alongside a 30.7% return on equity and a fortress-like balance sheet characterized by minimal debt and strong cash generation. While the nine-year price trajectory shows a net decline, the most recent annual performance is a strong 28.2% gain, signaling a successful turnaround that analysts are pricing in with a target mean of $129. The short-term view is more cautious; the stock has slipped nearly 12% over the last two weeks and is trading below its fifty-day moving average, creating a temporary headwind. However, the 200-day average provides a solid floor, and the options market shows significant call interest at higher strikes, suggesting smart money expects a rebound. There is no dividend income to rely on, so capital appreciation is the sole driver. The tension lies between the recent technical weakness and the superior underlying business metrics, which ultimately point to a high-conviction hold or buy for the long horizon. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.029717 |
| MSTL | 0.032910 |
| AutoTheta | 0.094187 |
| AutoARIMA | 0.166797 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 0.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.362 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.603 |
| Revenue per Share | 29.361 |
| Market Cap | 22,919,032,832 |
| Trailing P/E | 14.40 |
| Forward P/E | 13.03 |
| Beta | 0.74 |
| Profit Margins | 27.71% |
| Website | https://www.incyte.com |
As of Oct. 10, 2026, 9:43 a.m. EDT: Speculators are positioning for a significant upside move to the $165 range while simultaneously hedging downside risks around the $95-$110 zone. Call open interest is concentrated at strikes significantly above the current price, indicating bullish bets on a recovery, whereas heavy put open interest at lower strikes suggests investors are protecting against further volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.3121736 |
| Address1 | 1,801 Augustine Cut-Off |
| All Time High | 153.15 |
| All Time Low | 1.65625 |
| Ask | 121.27 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 1,819,080 |
| Average Daily Volume3 Month | 1,644,467 |
| Average Volume | 1,644,467 |
| Average Volume10Days | 1,819,080 |
| Beta | 0.739 |
| Bid | 104.46 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 31.568 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 113.07 |
| Current Ratio | 4.593 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 114.56 |
| Day Low | 112.02 |
| Debt To Equity | 0.603 |
| Display Name | Incyte |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,304,000 |
| Earnings Call Timestamp Start | 1,793,304,000 |
| Earnings Growth | 0.377 |
| Earnings Quarterly Growth | 0.446 |
| Earnings Timestamp | 1,793,277,000 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | 1,942,312,960 |
| Ebitda Margins | 0.33376 |
| Enterprise To Ebitda | 9.484 |
| Enterprise To Revenue | 3.165 |
| Enterprise Value | 18,421,561,344 |
| Eps Current Year | 3.12076 |
| Eps Forward | 8.67825 |
| Eps Trailing Twelve Months | 7.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 121.834 |
| Fifty Day Average Change | -8.764 |
| Fifty Day Average Change Percent | -0.07193394 |
| Fifty Two Week Change Percent | 31.217361 |
| Fifty Two Week High | 132.6 |
| Fifty Two Week High Change | -19.530006 |
| Fifty Two Week High Change Percent | -0.1472851 |
| Fifty Two Week Low | 84.02 |
| Fifty Two Week Low Change | 29.050003 |
| Fifty Two Week Low Change Percent | 0.34575105 |
| Fifty Two Week Range | 84.02 - 132.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 752,423,400,000 |
| Float Shares | 170,405,968 |
| Forward Eps | 8.67825 |
| Forward P E | 13.029124 |
| Free Cashflow | 1,180,664,576 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,844 |
| Fullday Change | -0.9699936 |
| Fullday Change Percent | -0.85635525 |
| Fullday Price | 113.07 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.55659 |
| Gross Profits | 3,239,065,088 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01845 |
| Held Percent Institutions | 1.03589 |
| Implied Shares Outstanding | 202,697,746 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 967,766,400 |
| Last Split Factor | 2:1 |
| Long Business Summary | Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. |
| Long Name | Incyte Corporation |
| Market | us_market |
| Market Cap | 22,919,032,832 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_332954 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 1,612,382,976 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 25,728,424,899 |
| Number Of Analyst Opinions | 24 |
| Open | 113.96 |
| Operating Cashflow | 1,979,703,040 |
| Operating Margins | 0.41899 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 10.82 |
| Phone | 302 498 6700 |
| Post Market Change | -0.76999664 |
| Post Market Change Percent | -0.6809911 |
| Post Market Price | 112.3 |
| Post Market Time | 1,792,194,886 |
| Previous Close | 113.27 |
| Price Eps Current Year | 36.23156 |
| Price Hint | 2 |
| Price To Book | 3.5817916 |
| Price To Sales Trailing12 Months | 3.938296 |
| Profit Margins | 0.27706 |
| Quick Ratio | 4.314 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.25 |
| Region | US |
| Regular Market Change | -0.199997 |
| Regular Market Change Percent | -0.176567 |
| Regular Market Day High | 114.56 |
| Regular Market Day Low | 112.02 |
| Regular Market Day Range | 112.02 - 114.56 |
| Regular Market Open | 113.96 |
| Regular Market Previous Close | 113.27 |
| Regular Market Price | 113.07 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 1,580,116 |
| Return On Assets | 0.16832 |
| Return On Equity | 0.30667 |
| Revenue Growth | 0.377 |
| Revenue Per Share | 29.361 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 202,697,746 |
| Shares Percent Shares Out | 0.0493 |
| Shares Short | 9,987,084 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,364,687 |
| Short Name | Incyte Corporation |
| Short Percent Of Float | 0.084 |
| Short Ratio | 6.5 |
| Source Interval | 15 |
| State | DE |
| Symbol | INCY |
| Target High Price | 157.0 |
| Target Low Price | 86.0 |
| Target Mean Price | 129.5 |
| Target Median Price | 129.0 |
| Total Cash | 4,535,739,904 |
| Total Cash Per Share | 22.377 |
| Total Debt | 38,267,000 |
| Total Revenue | 5,819,530,240 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 7.85 |
| Trailing P E | 14.403822 |
| Trailing Peg Ratio | 10.8221 |
| Triggerable | 1 |
| Two Hundred Day Average | 107.49905 |
| Two Hundred Day Average Change | 5.5709534 |
| Two Hundred Day Average Change Percent | 0.05182328 |
| Type Disp | Equity |
| Volume | 1,580,116 |
| Website | https://www.incyte.com |
| Zip | 19,803 |